ATM and neoplasm: Targeted NGS using our institutional CLIA-certified OncoPanel assay27 showed that only one patient (1.8%) had a tumor with an ATM mutation (ATM c.3078-5_3078-4insC), which also exhibited negative ATM protein expression by IHC.